Scott Bertram, a director at Becton Dickinson & Co. (NYSE:BDX), recently sold 700 shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission. The ...

Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately, Piper Sandler ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Becton Dickinson (BDX) is a global medical technology company comprised of essentially two businesses: (i) MedTech, which consists of the BD Medical (medication delivery and management solutions ...

Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic ...

Stock Market Value: ~$66.65B ($229.85 per share) Becton Dickinson (BDX) is a global medical technology company comprised of essentially two businesses: (i) MedTech, which consists of the BD ...